{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:33:39Z","timestamp":1767706419435},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5911,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1093\/annonc\/mdg461","type":"journal-article","created":{"date-parts":[[2003,10,28]],"date-time":"2003-10-28T02:19:28Z","timestamp":1067307568000},"page":"1660-1666","source":"Crossref","is-referenced-by-count":48,"title":["Paclitaxel for anthracycline-resistant AIDS-related Kaposi\u2019s sarcoma: clinical and angiogenic correlations"],"prefix":"10.1016","volume":"14","author":[{"given":"J.","family":"Stebbing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wildfire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Portsmouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thirlwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mandalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gotch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.G.","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg461_bb0010","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/00002030-199714000-00010","article-title":"Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy","volume":"11","author":"Brodt","year":"1997","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/jnci\/92.22.1823","article-title":"Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults","volume":"92","author":"International Collaboration on HIV and Cancer","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdg461_bb0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00002030-199710001-00007","article-title":"Reduction of Kaposi\u2019s sarcoma lesions following treatment of AIDS with ritonovir","volume":"11","author":"Conant","year":"1997","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0025","first-page":"261","article-title":"Regression of AIDS-related Kaposi\u2019s sarcoma following treatment with an HIV-1 protease inhibitor","volume":"11","author":"Murphy","year":"1997","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-199912010-00014","article-title":"HAART is effective as anti-Kaposi\u2019s sarcoma therapy only after remission has been induced by chemotherapy","volume":"22","author":"Vaccher","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1093\/annonc\/mdg461_bb0035","first-page":"368","article-title":"Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy","volume":"9","author":"Winceslaus","year":"1998","journal-title":"Int J STD AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0040","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi\u2019s sarcoma","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0045","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1128\/JVI.73.7.6136-6140.1999","article-title":"Identification of human herpesvirus 8-specific cytotoxic T-cell responses","volume":"73","author":"Osman","year":"1999","journal-title":"J Virol"},{"key":"10.1093\/annonc\/mdg461_bb0050","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/1521-4141(2002010)32:10<2711::AID-IMMU2711>3.0.CO;2-3","article-title":"NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi\u2019s sarcoma","volume":"32","author":"Sirianni","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1093\/annonc\/mdg461_bb0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jama.286.2.196","article-title":"HIV-1 drug resistance profiles in children and adults with viral load of <50 copies\/ml receiving combination therapy","volume":"286","author":"Hermankova","year":"2001","journal-title":"J Am Med Assoc"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdg461_bb0060","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00002030-200102002-00003","article-title":"Immune restoration and CD4+ T-cell function with antiretroviral therapies","volume":"15","author":"Lederman","year":"2001","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00002018-199920050-00002","article-title":"A risk and benefit assessment of treatment for AIDS-related Kaposi\u2019s sarcoma","volume":"20","author":"Nasti","year":"1999","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdg461_bb0070","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0075","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma. International Pegylated Liposomal Doxorubicin Study Group","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0085","first-page":"1121","article-title":"Treatment of Kaposi\u2019s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine\u2013vinblastine regimen","volume":"70","author":"Kaplan","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdg461_bb0090","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2000.18.7.1550","article-title":"Vinorelbine is an effective and safe drug for AIDS-related Kaposi\u2019s sarcoma: results of a phase II study","volume":"18","author":"Nasti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000421-199008000-00010","article-title":"Treatment of advanced Kaposi\u2019s sarcoma using a combination of bleomycin and vincristine","volume":"13","author":"Gill","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0100","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi\u2019s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine","volume":"2","author":"Laubenstein","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(95)92654-2","article-title":"Treatment of HIV-associated Kaposi\u2019s sarcoma with paclitaxel","volume":"346","author":"Saville","year":"1995","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdg461_bb0110","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1998.16.3.1112","article-title":"Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi\u2019s sarcoma","volume":"16","author":"Welles","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0115","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi\u2019s sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg461_bb0125","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg461_bb0130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00002030-199605000-00010","article-title":"Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi\u2019s sarcoma","volume":"10","author":"Uthayakumar","year":"1996","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0135","first-page":"1412","article-title":"Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi\u2019s sarcoma","volume":"11","author":"White","year":"1997","journal-title":"AIDS"},{"key":"10.1093\/annonc\/mdg461_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma","volume":"8","author":"Sgadari","year":"2002","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdg461_bb0145","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg461_bb0150","first-page":"314","article-title":"1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals","volume":"352","author":"Gazzard","year":"1998","journal-title":"BHIVA Guidelines Writing Committee. Lancet"},{"key":"10.1093\/annonc\/mdg461_bb0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1046\/j.1464-2662.2001.00083.x","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy","volume":"2","year":"2001","journal-title":"HIV Med"},{"key":"10.1093\/annonc\/mdg461_bb0160","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1997.15.9.3085","article-title":"AIDS-related Kaposi\u2019s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee","volume":"15","author":"Krown","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg461_bb0165","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0959-8049(01)00109-5","article-title":"Clinical aspects and management of AIDS-related Kaposi\u2019s sarcoma","volume":"37","author":"Levine","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdg461_bb0170","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","article-title":"The treatment of advanced renal cell cancer with high-dose oral thalidomide","volume":"85","author":"Stebbing","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg461_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1309\/7243-AV50-KJ28-V6J9","article-title":"Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection","volume":"117","author":"Menke","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1093\/annonc\/mdg461_bb0180","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/clc.4960251106","article-title":"Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina","volume":"25","author":"Rallidis","year":"2002","journal-title":"Clin Cardiol"},{"key":"10.1093\/annonc\/mdg461_bb0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.165.1.509","article-title":"Mechanism of paclitaxel activity in Kaposi\u2019s sarcoma","volume":"165","author":"Sgadari","year":"2000","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdg461_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis","volume":"11","author":"Vacca","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1093\/annonc\/mdg461_bb0195","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.285.13.1736","article-title":"Association of cancer with AIDS-related immunosuppression in adults","volume":"285","author":"Frisch","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1093\/annonc\/mdg461_bb0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002030-199902040-00019","article-title":"Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"13","author":"Schwartz","year":"1999","journal-title":"AIDS"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419642237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419642237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/11\/1660\/478681\/mdg461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T21:17:25Z","timestamp":1582233445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419642237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0923753419642237"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg461","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}